Mark Ragosa Sells 36,372 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 36,372 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $22.61 on Friday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48. The firm has a 50 day simple moving average of $19.99 and a 200 day simple moving average of $22.16. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s quarterly revenue was up 46.9% on a year-over-year basis. During the same period last year, the firm earned $0.35 earnings per share. As a group, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Jefferies Financial Group Inc. increased its stake in Kiniksa Pharmaceuticals by 39.5% in the fourth quarter. Jefferies Financial Group Inc. now owns 112,400 shares of the company’s stock valued at $2,223,000 after purchasing an additional 31,800 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Kiniksa Pharmaceuticals by 28.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company’s stock valued at $1,121,000 after purchasing an additional 12,462 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $530,000. State of Wyoming bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $293,000. Finally, ProShare Advisors LLC increased its stake in Kiniksa Pharmaceuticals by 35.5% in the fourth quarter. ProShare Advisors LLC now owns 12,807 shares of the company’s stock valued at $253,000 after purchasing an additional 3,357 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KNSA. Wedbush reiterated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.